ES2176009T3 - Utilizacion de cloruro de sodio para reducir la toxicidad gastrointestinal de los derivados de la competencia. - Google Patents

Utilizacion de cloruro de sodio para reducir la toxicidad gastrointestinal de los derivados de la competencia.

Info

Publication number
ES2176009T3
ES2176009T3 ES99936674T ES99936674T ES2176009T3 ES 2176009 T3 ES2176009 T3 ES 2176009T3 ES 99936674 T ES99936674 T ES 99936674T ES 99936674 T ES99936674 T ES 99936674T ES 2176009 T3 ES2176009 T3 ES 2176009T3
Authority
ES
Spain
Prior art keywords
sodium chloride
derivatives
competition
gastrointestinal toxicity
reduce gastrointestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99936674T
Other languages
English (en)
Inventor
Herve Toutain
Magali Guffroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9810043A external-priority patent/FR2782009B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2176009T3 publication Critical patent/ES2176009T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Utilización de cloruro de sodio para la preparación de un agente destinado a disminuir o a suprimir los efectos secundarios gastro-intestinales inducidos por la administración de derivados de la camptotecina, caracterizada porque la solución de cloruro de sodio se administra por vía oral.
ES99936674T 1998-08-05 1999-08-03 Utilizacion de cloruro de sodio para reducir la toxicidad gastrointestinal de los derivados de la competencia. Expired - Lifetime ES2176009T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810043A FR2782009B1 (fr) 1998-08-05 1998-08-05 Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite
US9631898P 1998-08-12 1998-08-12

Publications (1)

Publication Number Publication Date
ES2176009T3 true ES2176009T3 (es) 2002-11-16

Family

ID=26234482

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99936674T Expired - Lifetime ES2176009T3 (es) 1998-08-05 1999-08-03 Utilizacion de cloruro de sodio para reducir la toxicidad gastrointestinal de los derivados de la competencia.

Country Status (24)

Country Link
US (1) US6476043B1 (es)
EP (1) EP1102594B1 (es)
JP (1) JP2002522392A (es)
KR (1) KR20010072228A (es)
AT (1) ATE217531T1 (es)
AU (1) AU771195B2 (es)
BG (1) BG64641B1 (es)
CA (1) CA2340020A1 (es)
CZ (1) CZ295775B6 (es)
DE (1) DE69901506T2 (es)
DK (1) DK1102594T3 (es)
EA (1) EA002917B1 (es)
EE (1) EE04264B1 (es)
ES (1) ES2176009T3 (es)
GE (1) GEP20043254B (es)
HU (1) HUP0103314A3 (es)
ID (1) ID27253A (es)
IL (1) IL141232A0 (es)
NO (1) NO20010454D0 (es)
NZ (1) NZ509859A (es)
PT (1) PT1102594E (es)
SK (1) SK1732001A3 (es)
TR (1) TR200100331T2 (es)
WO (1) WO2000007605A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1749540B1 (en) 1999-05-17 2010-10-13 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
EP1714653B1 (en) * 2004-02-13 2010-11-24 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing a camptothecin
US20050197355A1 (en) * 2004-03-02 2005-09-08 Henegar Kevin E. Compounds useful in preparing camptothecin derivatives
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP2006151950A (ja) * 2004-11-05 2006-06-15 Oto Corporation:Kk 納豆菌培養エキス含有製剤及び納豆菌培養エキスの保存方法
ATE446299T1 (de) * 2005-02-07 2009-11-15 Fermion Oy Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
JP5133704B2 (ja) * 2005-02-08 2013-01-30 フェルミオン オサケ ユキチュア 製造方法
CA2591071C (en) * 2005-02-08 2014-04-29 Fermion Oy Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
US7994186B2 (en) * 2005-04-18 2011-08-09 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
CA2612949C (en) 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284579A (en) * 1979-07-17 1981-08-18 The United States Of America As Represented By The Of The Department Of Health & Human Services (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
CA1332413C (en) * 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
IT1247937B (it) * 1991-05-16 1995-01-05 Ist Naz Ric Sul Cancro Associazione farmaceutica ad attivita' antineoplastica
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases

Also Published As

Publication number Publication date
AU5168799A (en) 2000-02-28
ID27253A (id) 2001-03-22
NO20010454L (no) 2001-01-26
BG105216A (en) 2001-10-31
WO2000007605A1 (fr) 2000-02-17
ATE217531T1 (de) 2002-06-15
US6476043B1 (en) 2002-11-05
BG64641B1 (bg) 2005-10-31
AU771195B2 (en) 2004-03-18
DE69901506T2 (de) 2002-11-28
DE69901506D1 (de) 2002-06-20
NO20010454D0 (no) 2001-01-26
HUP0103314A3 (en) 2002-07-29
NZ509859A (en) 2003-09-26
EA002917B1 (ru) 2002-10-31
EP1102594A1 (fr) 2001-05-30
CZ295775B6 (cs) 2005-11-16
KR20010072228A (ko) 2001-07-31
HUP0103314A2 (hu) 2002-01-28
EE04264B1 (et) 2004-04-15
EP1102594B1 (fr) 2002-05-15
IL141232A0 (en) 2002-03-10
SK1732001A3 (en) 2001-06-11
TR200100331T2 (tr) 2001-07-23
GEP20043254B (en) 2004-06-25
CA2340020A1 (fr) 2000-02-17
PT1102594E (pt) 2002-10-31
CZ2001382A3 (en) 2001-05-16
DK1102594T3 (da) 2002-08-26
JP2002522392A (ja) 2002-07-23
EA200100214A1 (ru) 2001-08-27
EE200100066A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
BR0115910A (pt) Compostos orgânicos
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ATE174899T1 (de) Zytotoxische stilben-derivate und diese enthaltende pharmazeutische zusammensetzungen
DK0396165T3 (da) Farmaceutisk præparat til oral indgift til gastrointestinal udskylning eller som katarlaxativ
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
KR890016966A (ko) 신규 항바이러스제
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
SE9002500L (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
PE68899A1 (es) Composicion que contiene paracetamol
PT1102594E (pt) Utilizacao de cloreto de sodio para reduzir a toxicidade gastrointestinal de derivados de camptotecina
BR9809571A (pt) Composição medicinal e processo para produzì-la
AR018198A1 (es) Soluciones estables de mitoxantrona, procedimiento para prepararlas, utilizacion de dichas soluciones para la preparacion de medicamentos y losmedicamentos de aplicacion de dichas soluciones para el tratamiento de enfermedades cancerosas
IL154755A0 (en) Antitumor theraphy comprising distamycin derivatives
ES2179526T3 (es) Analogos y profarmacos del paclitaxel solubles en agua.
BR0014687A (pt) Compostos de taxano pentacìclico
ES2062724T3 (es) Utilizacion de derivados de la triazina y de la pirimidina para la obtencion de medicamentos que combaten la resistencia a los agentes anticancerosos y antimalaricos.
MEP1108A (en) Use of specific dose of fondaparinux sodium for the treatment of acs
BG105178A (bg) Нови 2,3,3а,4,9,9а-хексахидро-8-хидрокси-1н-бенз/f/индоли, метод за получаването им и приложението им като лекарствени средства
BR9912765A (pt) Utilização de cloreto de sódio
FR2308368A1 (fr) Sel soluble de la cephalexine comme antibiotique injectable
SI1102594T1 (en) Use of sodium chloride to reduce the gastrointestinal toxicity of camptothecin derivatives
SE9803279D0 (sv) Novel compounds
TH45067A (th) วิธีสำหรับการลดไฟบริโนเจน
EA199800848A1 (ru) Гиполипидемическое и антиатеросклеротическое средство

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1102594

Country of ref document: ES